We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has cited Boehringer Ingelheim Pharmaceuticals for running a journal advertisement containing unsubstantiated superiority claims about its stroke drug Aggrenox.